ArticleBlood2011
Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00661804 (A Longitudinal Cohort Study of Patients With Thalassemia in the Thalassemia Clinical Research Network), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Longitudinal Cohort Study of Patients With Thalassemia in the Thalassemia Clinical Research Network
Who cites it
19 citing papers in PubMed, 66 citations in OpenAlex.
- Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension.Haematologica · 2013Trial
- Aging with Thalassemia and Sickle Cell Disease: A Gerontological Model of Accelerated Multimorbidity and Function-Centered Care Beyond Midlife.Mediterranean journal of hematology and infectious diseases · 2026Review
- Determinants of Multi-Organ Morbidity in Neo-Transfusion-Dependent Thalassemia: A Cross-Sectional Analysis.Journal of clinical medicine · 2025Article
- The predicting formula and scoring system for cardiac iron overload for thalassaemia children: Study from a middle-income country.PloS one · 2024Article
- Cardiac complications in thalassemia throughout the lifespan: Victories and challenges.Annals of the New York Academy of Sciences · 2023Review
- Non-Transfusion-Dependent Thalassemia: A Panoramic Review.Medicina (Kaunas, Lithuania) · 2022Review
- Tricuspid-valve regurgitant jet velocity as a risk factor for death in β-thalassemia.Haematologica · 2022Article
- The microbiota-gut-brain axis: An emerging role for the epigenome.Experimental biology and medicine (Maywood, N.J.) · 2020Review
- Article
- Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension.Frontiers in medicine · 2020Review
- Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major.Redox report : communications in free radical research · 2017Article
- HbE/β-Thalassemia and Oxidative Stress: The Key to Pathophysiological Mechanisms and Novel Therapeutics.Antioxidants & redox signaling · 2017Review
- Pulmonary hypertension associated with thalassemia syndromes.Annals of the New York Academy of Sciences · 2016Review
- Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia.British journal of haematology · 2015Article
- Pulmonary hypertension in well-transfused thalassemia major patients.Blood cells, molecules & diseases · 2015Article
- Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy.Annals of hematology · 2014Article
- Article
- Increased tricuspid regurgitant jet velocity by Doppler echocardiography in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Article
- Pathophysiology and Clinical Manifestations of the β-Thalassemias.Cold Spring Harbor perspectives in medicine · 2012Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 11 institutions in 3 countries.
Funding
Abstract
An elevated tricuspid regurgitant jet velocity (TRV) is associated with hemolysis and early mortality in sickle cell disease, yet risk factors, clinical parameters, and mortality associated with this biomarker in thalassemia are poorly defined. This report summarizes the prevalence of an elevated TRV in 325 patients screened by Doppler echocardiography in the Thalassemia Clinical Research Network. A documented TRV was reported in 148 of 325 (46%) of patients. Average age was 25.9 years (range, 5-56 years) and 97% were transfusion-dependent. Mean TRV was 2.3 ± 0.4 m/s (range, 0.2-3.5 m/s). An abnormal TRV ≥ 2.5 m/s was identified in 49 of 148 (33%) of patients with a documented TRV, 5% (8/148), with a TRV ≥ 3.0 m/s, suggesting significant PH risk. Older age was strongly associated with a high TRV; however, 16% of children had a TRV ≥ 2.5 m/s. A history of splenectomy, hepatitis C, smoking, or high white blood cell count was associated with TRV elevation. In summary, an elevated TRV is noted in one-third of transfusion-dependent thalassemia patients with a documented value and develops in both children and adults. Age, splenectomy, hepatitis C, and smoking are significant univariate risk factors, with splenectomy surfacing as the dominant risk factor over time. Mortality was low in this cohort. Prospective longitudinal studies are needed. This study is registered at http://www.clinicaltrials.gov as NCT00661804.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.